8-K: Rigel R289 Phase 1b MDS Data Shows Efficacy, Tolerability

Rigel Pharmaceuticals announced updated Phase 1b study data for R289 in lower-risk myelodysplastic syndrome, showing preliminary efficacy and good tolerability.

Summary

• Updated data from the ongoing Phase 1b study evaluating R289 in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS) was presented.
• R289, an oral prodrug of R835 (a dual inhibitor of IRAK1/4), was generally well tolerated across all dose groups in a heavily pre-treated, elderly patient population (median age 75, median 3 prior therapies).
• 33% (6/18) of evaluable transfusion-dependent patients receiving R289 doses of at least 500 mg QD achieved durable red blood cell transfusion independence (RBC-TI) of greater than 8 weeks.
• This included 40% (2/5) of patients in the 500 mg BID dose group achieving RBC-TI.
• The median time to onset of RBC-TI was 1.9 months, and the median duration of RBC-TI was 22.9 weeks.
• Patients achieving RBC-TI experienced peak hemoglobin increases ranging from 2.9 to 6.1 g/dL compared to baseline.
• R289 has been granted Orphan Drug designation for MDS and Fast Track designation for previously-treated transfusion-dependent lower-risk MDS by the FDA.

Sentiment

Score: 8

Explanation: The data presented for R289 in a difficult-to-treat patient population shows promising preliminary efficacy and good tolerability, supported by FDA designations. While early-stage, these results are a strong positive signal for the drug's potential.

Positives

• R289 was generally well tolerated across all dose groups in a difficult-to-treat, heavily pre-treated elderly lower-risk MDS patient population.
• Preliminary efficacy was observed, with 33% (6/18) of evaluable transfusion-dependent patients achieving durable red blood cell transfusion independence (RBC-TI) of greater than 8 weeks at doses of at least 500 mg QD.
• A higher RBC-TI rate of 40% (2/5) was observed in the 500 mg BID dose group.
• The median duration of RBC-TI was substantial at 22.9 weeks, with some patients maintaining independence for over 16 weeks and over 24 weeks.
• Significant peak hemoglobin increases (2.9 to 6.1 g/dL) were noted in patients who achieved RBC-TI.
• R289 has received Orphan Drug designation for MDS and Fast Track designation for previously-treated transfusion-dependent lower-risk MDS from the FDA, highlighting its potential to address an unmet medical need and potentially expedite development.

Negatives

• The most common Grade 1/2 treatment-emergent adverse events (TEAEs) (in at least 18% of patients) included diarrhea (30%), constipation and fatigue (each 27%), and creatinine increased and cough (each 21%).
• The most frequent Grade 3/4 TEAEs were anemia (18%), neutrophil count decreased and pneumonia (each 15%), and alanine aminotransferase (ALT) increased and aspartate aminotransferase (AST) increased (each 9%).
• One dose limiting toxicity (DLT) (Grade 4 AST increased/Grade 3 ALT increased) was reported in the 750 mg dose group.

Risks

• Risks and uncertainties of clinical trials and drug development.
• Risks and uncertainties associated with the commercialization and marketing of R289.
• Risks that the FDA or other regulatory authorities may make adverse decisions regarding R289.
• Risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials.
• Risks that R289 may have unintended side effects, adverse reactions, or incidents of misuses.
• The availability of resources to develop product candidates.
• Market competition.
• Other risks detailed from time to time in reports filed with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and subsequent filings.

Future Outlook

Rigel anticipates concluding the dose expansion phase of the R289 study and selecting the recommended Phase 2 dose for future clinical studies in the second half of 2026. The company believes R289 has the potential to become a new treatment option for patients with transfusion-dependent lower-risk MDS.

Management Comments

• "We're pleased to share these updated study results, which underscore the potential of R289 to become a treatment option for these patients." Lisa Rojkjaer, M.D., Rigel's chief medical officer.
• "We look forward to concluding the dose expansion phase of the study and anticipate selection of the recommended Phase 2 dose for future clinical studies in the second half of 2026." Lisa Rojkjaer, M.D., Rigel's chief medical officer.

Industry Context

New therapies are critically needed for patients with transfusion-dependent lower-risk MDS, particularly for elderly, heavily pre-treated populations who have failed existing treatments such as luspatercept, erythropoiesis stimulating agents (ESAs), hypomethylating agents (HMAs), and imetelstat. R289, as an IRAK1/4 dual inhibitor, offers a novel mechanism of action by targeting inflammatory pathways implicated in MDS pathogenesis, addressing a significant unmet medical need in this disease area.

Comparison to Industry Standards

• The study population represents a difficult-to-treat group, with a median age of 75 and a median of 3 prior therapies, including 76% who received luspatercept, 73% an ESA, 67% an HMA, and 6% imetelstat. This indicates R289 is being tested in patients who have exhausted standard options, making any observed efficacy notable.
• The 33% RBC-TI rate in this heavily pre-treated population is a positive signal, especially given the high unmet need for new therapies in transfusion-dependent lower-risk MDS.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial data for a pipeline asset, potentially increasing future revenue streams and market valuation.
• Patients: Potential for a new treatment option for a difficult-to-treat, transfusion-dependent lower-risk MDS patient population with high unmet medical need.
• Employees: Continued progress in clinical development supports job security and potential for future growth.

Next Steps

• Conclude the dose expansion phase of the R289 Phase 1b study.
• Select the recommended Phase 2 dose for future clinical studies in the second half of 2026.

Key Dates

Recommendation

The updated Phase 1b data for R289 in lower-risk MDS is highly encouraging, demonstrating both preliminary efficacy (33% RBC-TI in a heavily pre-treated population) and good tolerability. The patient cohort is particularly challenging, having failed multiple prior therapies, which makes these results more significant. The FDA's Orphan Drug and Fast Track designations further de-risk the development pathway and highlight the unmet medical need. While early-stage, these positive signals suggest R289 has strong potential to address a critical patient population, warranting a "buy" recommendation for investors looking for growth in the biotechnology sector, especially given the anticipated Phase 2 dose selection in H2 2026.

Keywords

Rigel Pharmaceuticals, R289, Myelodysplastic Syndrome, MDS, Lower-Risk MDS, Relapsed/Refractory, IRAK1/4 inhibitor, Clinical Trial, Phase 1b, Hematologic Disorders, Biotechnology, Transfusion Independence, ASH Annual Meeting, Orphan Drug, Fast Track, Oncology